Zooming in on Cerebral Abnormalities in Severely Affected COVID-19 Patients
ZoomCOVID
ZoomCOVID
Sponsor study identifier
observational
70
1 country
1
Study Start
June 20, 2022
Actual (reported)Primary Completion
October 2024
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
October 2024
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Brain injury is one of the complications in COVID-19 intensive care unit (ICU) survivors, though the precise underlying mechanism is unclear. It is likely caused by a combination of prolonged hypoxia, a massive systemic inflammatory response, direct infection of the brain and small vessel vasculitis in combination with widespread hypercoagulopathy and thrombosis. Using novel MRI techniques, blood-brain barrier (BBB) permeability, as well as other microstructural and microvascular properties of the brain tissue, will be assessed non-invasively in COVID-19 ICU survivors approximately one year after ICU admission and compared to serial clinical and laboratory measurements of hypercoagulation and inflammation during the (ICU) admission. This study aims to relate factors of hypercoagulability, inflammation or general illness itself (all during ICU admission) to microstructural and microvascular abnormalities on follow-up brain advanced 3T and 7T MRI in COVID-19 ICU survivors. In addition, neuropsychological tests and an objective smell/taste test will be used to evaluate neuropsychological status and sense of smell/taste. By gaining more insight into the pathogenesis of brain injury, the treatment of COVID-19 patients in the acute phase might be improved.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
October 2024
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
January 17, 2022
Actual (reported)January 19, 2022
Actual (reported)June 20, 2022
Actual (reported)October 2024
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
October 2024
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Radiological outcome
MRI abnormalities, focusing on vascular abnormalities and olfactory tractus (3T MRI), and lymphatics and the brainstem (7T MRI).
12-24 months post ICU admission
Neurological outcome
Residual neurological symptoms (including sense of smell/taste) and functional status.
12-24 months post ICU admission
Clinical outcome
severity of disease scores, (serial) factors of hyper coagulability and inflammation during ICU admission, neurological and cardiovascular (arterial/venous) complications during hospital admission.
12-24 months post ICU admission
Neuropsychological outcome
12-24 months post ICU admission
The population consists of adult patients who survived a COVID-19 infection for which ICU hospital admission was necessary during the second/third pandemic wave (October 2020 - ongoing).
Maastricht University Medical Center+
Maastricht, Limburg, 6229HX, Netherlands
Blood (approximately 20mL in total) will be drawn using heparin, EDTA, serum and citrate tubes to evaluate markers for hypercoagulation and inflammation.
Marcel JH Ariës, PhD/MD
Maastricht University Medical Center
First Submitted
January 17, 2022
First Posted
January 19, 2022
Study Start
June 20, 2022
Actual (reported)Primary Completion
October 2024
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Availability and Advice on Test Uptake During the COVID-19 Pandemic: a Vignette Study.
Contact the study team to confirm eligibility.
Study Completion
October 2024
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
June 29, 2022
Record last verified: 2022-06
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: